

AMENDMENTS TO THE CLAIMS

The following listing of claims replaces all prior versions and listings of claims in this application.

1. (Original) An isolated polynucleotide comprising a transcript of a T cell receptor (TCR) gene, said polynucleotide lacking V region sequences and comprising a constant (C) domain and joining (J) region sequences, and a 5' intronic J sequences upstream to said J region sequence including an in-frame methionine codon.
2. (Original) The polynucleotide according to claim 1, wherein the gene is a TCR β gene.
3. (Original) The polynucleotide according to claim 2, wherein the joining (J) gene sequence is selected from J β 2.1 and J β 2.6.
4. (Original) The polynucleotide according to claim 3, wherein the joining (J) gene sequence is J β 2.1 and said 5' intronic J sequence including an in-frame methionine codon codes for a peptide of the sequence M E N V S N P G S C I E E G E E R G R I L G S P F L [SEQ ID NO:1].
5. (Original) The polynucleotide according to claim 3, wherein the joining (J) gene sequence is J β 2.6 and said 5' intronic J sequence including a methionine codon codes for a peptide of the sequence M G E Y L A E P R G F V C G V E P L C [SEQ ID NO: 2].
6. (Original) The polynucleotide according to claim 1, comprising a 5' intronic J sequence encoding a peptide selected from any one of SEQ ID NOs:1-37.
7. (Original) The polynucleotide of claim 2, wherein the joining J gene sequence is the intronic J β 2.3 gene sequence coding for the peptide:

M G L S A V G R T R A E S G T A E R A A P V F V L G L Q A V [SEQ ID NO: 17].

8. (Original) The polynucleotide according to claim 1, wherein the gene is a TCR α gene.

9. (Original) The cDNA molecule according to claim 8, wherein the joining (J) gene sequence is selected from human or murine J α genes.

10. (Currently amended) The cDNA molecule according to claim 9, wherein said 5' intronic J sequence including an in-frame methionine codon is selected from the group consisting of:

(i) the intronic J α TA31 gene sequence coding for the peptide:

M A W H [SEQ ~~IN~~ ID NO:3].

(ii) the intronic J α TA46 gene sequence coding for the peptide:

M E A G W E V Q H W V S D M E C L T V [SEQ ~~IN~~ ID NO:4].

(iii) the intronic J α TA46 gene sequence coding for the peptide:

M E C L T V [SEQ ~~IN~~ ID NO:5].

(iv) the intronic J α New05 gene sequence coding for the peptide:

M T V [SEQ ~~IN~~ ID NO:6].

(v) the intronic J α S58 gene sequence coding for the peptide:

M C G S E E V F V V E S A [SEQ ~~IN~~ ID NO:7].

(vi) the intronic J α New06 gene sequence coding for the peptide:

M A C Y Q M Y F T G R K V D E P S E L G S G L
E L S Y F H T G G S S Q A V G L F I E N M I S T S
H G H F Q E M Q F S I W S F T V L Q I S A P G S H
L V P E T E R A E G P G V F V E H D I [SEQ ~~IN~~ ID NO:8].

(vii) the intronic J α New06 gene sequence coding for the peptide:

M Y F T G R K V D E P S E L G S G L E L S Y F H T G G
S S Q A V G L F I E N M I S T S
H G H F Q E M Q F S I W S F T V L Q I S A P G S H

L V P E T E R A E G P G V F V E H D I [SEQ IN ID NO:9].

(viii) the intronic J α New06 gene sequence coding for the peptide:

M I S T S H G H F Q E M Q F S I W S F T V L Q I S A P G S H

L V P E T E R A E G P G V F V E H D I [SEQ IN ID NO:10].

(ix) the intronic J α New06 gene sequence coding for the peptide:

M Q F S I W S F T V L Q I S A P G S H

L V P E T E R A E G P G V F V E H D I [SEQ IN ID NO:11].

(x) the intronic J α New08 gene sequence coding for the peptide:

M W W G L I L S A S V K F L Q R K E I L C [SEQ IN ID NO:12].

(xi) the intronic J α LB2A gene sequence coding for the peptide:

M V G A D L C K G G W H C V [SEQ IN ID NO:13].

(xii) the intronic J α DK1 gene sequence coding for the peptide:

M R E P V K N L Q G L V S [SEQ IN ID NO:14].

(xiii) the intronic J α TA39 gene sequence coding for the peptide:

M E V Y E L R V T L M E T G R E R S H F V K T S L [SEQ IN ID NO:15];

and

(xiv) the intronic J α TA39 gene sequence coding for the peptide:

M E T G R E R S H F V K T S L [SEQ IN ID NO:16].

11. (Currently amended) The polynucleotide according to claim 8, wherein said 5' intronic J sequence including an in-frame methionine codon is selected from the group consisting of:

(i) the intronic J α 3 gene sequence coding for the peptide:

M L L W D P S G F Q Q I S I K K V I S K T L P T [SEQ IN ID NO:18].

(ii) the intronic J α 6 gene sequence coding for the peptide:

M L P N T M G Q L V E G G H M K Q V L S K A V L T V [SEQ IN ID NO:19].

(iii) the intronic J α 6 gene sequence coding for the peptide:

M G Q L V E G G H M K Q V L S K A V L T V [SEQ IN ID NO:20].

(iv) the intronic J α 6 gene sequence coding for the peptide:

M K Q V L S K A V L T V [SEQ IN ID NO:21].

(v) the intronic J α 8 gene sequence coding for the peptide:

M S E C [SEQ ~~IN~~ ID NO:22].

(vi) the intronic J α 9 gene sequence coding for the peptide:

M A H F V A V Q I T V [SEQ ~~IN~~ ID NO:23].

(vii) the intronic J α 11 gene sequence coding for the peptide:

M G I C Y S [SEQ ~~IN~~ ID NO:24].

(viii) the intronic J α 13 gene sequence coding for the peptide:

M K R A G E G K S F C K G R H Y S V [SEQ ~~IN~~ ID NO:25].

(ix) the intronic J α 14 gene sequence coding for the peptide:

M L T T L I Y Y Q G N S V I F V R Q H S A [SEQ ~~IN~~ ID NO:26].

(x) the intronic J α 24 gene sequence coding for the peptide:

M Q L P H F V A R L F P H E Q F V F I Q Q L S S L G K P F C R G V C H S V
[SEQ ~~IN~~ ID NO:27].

(xi) the intronic J α 31 gene sequence coding for the peptide:

M G F S K G R K C C G [SEQ ~~IN~~ ID NO:28].

(xii) the intronic J α 36 gene sequence coding for the peptide:

M K K I W L S R K V F L Y W A E T L [SEQ ~~IN~~ ID NO:29].

(xiii) the intronic J α 40 gene sequence coding for the peptide:

M G K V H V M P L L F M E S K A A S I N G N I M L V Y V E T H N T V [SEQ
~~IN~~ ID NO:30].

(xiv) the intronic J α 40 gene sequence coding for the peptide:

M P L L F M E S K A A S I N G N I M L V Y V E T H N T V [SEQ ~~IN~~ ID NO:31].

(xv) the intronic J α 40 gene sequence coding for the peptide:

M E S K A A S I N G N I M L V Y V E T H N T V [SEQ ~~IN~~ ID NO:32].

(xvi) the intronic J α 40 gene sequence coding for the peptide:

M L V Y V E T H N T V [SEQ ~~IN~~ ID NO:33].

(xvii) the intronic J α 41 gene sequence coding for the peptide:

M E E G S F I Y T I K G P W M T H S L C D C C V I G F Q T L A L I G I I G E G
T W W L L Q G V F C L G R T H C [SEQ ~~IN~~ ID NO:34].

(xviii) the intronic J α 41 gene sequence coding for the peptide:

M T H S L C D C C V I G F Q T L A L I G I I G E G T W W L L Q G V F C L G R
T H C [SEQ ~~IN~~ ID NO:35].

(xix) the intronic J α 44 gene sequence coding for the peptide:

M E S Q A T G F C Y E A S H S V [SEQ ~~IN~~ ID NO:36].

12. (Withdrawn) An antisense polynucleotide of the polynucleotides according to claim 1.

13. (Original) An expression vector comprising a polynucleotide according to claim 1.

14. (Original) A host cell comprising a vector according to claim 13, wherein the host is a mammalian cell.

15. (Original) Transfected mesenchymal human cells according to claim 14.

16. (Withdrawn, Currently Amended) A polypeptide encoded by a polynucleotide according to [[claims]] claim 1.

17. (Currently amended) A polynucleotide comprising SEQ ID NO:38.

18. (Withdrawn) A synthetic peptide deduced from an intronic J sequence of a TCR.

19. (Withdrawn) The synthetic peptide according to claim 18 selected from the group consisting of any one of SEQ ID Nos: 1-16 or SEQ ID Nos: 17-36.

20. (Withdrawn) An antibody raised against a peptide according to claim 18.

21. (Withdrawn) An antibody raised against a peptide according to claim 19.

22. (Withdrawn) A method for inducing mesenchymal cell growth comprising administering to a subject in need thereof transfected mesenchymal human cells comprising a polynucleotide according to claim 1, in an amount effective to induce mesenchymal cell growth.

23. (Withdrawn) The method according to claim 22, wherein the method induces wound healing.

24. (Withdrawn) A method for suppressing mesenchymal cell growth comprising administering to a subject in need thereof transfected mesenchymal human cells comprising a DNA molecule according to claim 12, in an amount effective to suppress mesenchymal cell growth.

25. (Withdrawn) The method according to claim 24, wherein the method suppresses carcinomas.

26. (Withdrawn) A method of marking mesenchymal cells comprising applying an antibody according to claim 20 to mesenchymal cells in an amount effective to mark the cells.